ReviewCancer2025

Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer.

Jacob M Sands et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.